title: Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.
abstract: Ertapenem is active against extended-spectrum-β-lactamase (ESBL)-producing Enterobacteriaceae organisms but inactive against Pseudomonas aeruginosa and Acinetobacter baumannii. Due to a lack of therapeutic data for ertapenem in the treatment of ESBL bloodstream infections (BSIs), group 2 carbapenems (e.g., imipenem or meropenem) are often preferred for treatment of ESBL-producing Enterobacteriaceae, although their antipseudomonal activity is unnecessary. From 2005 to 2010, 261 patients with ESBL BSIs were analyzed. Outcomes were equivalent between patients treated with ertapenem and those treated with group 2 carbapenems (mortality rates of 6% and 18%, respectively; P = 0.18).
authors.affiliation: Division of Infectious Diseases, Wayne State University, Detroit, Michigan, USA.
authors.forename: Vicki L
authors.initials: VL
authors.lastname: Collins
authors.forename: Dror
authors.initials: D
authors.lastname: Marchaim
authors.forename: Jason M
authors.initials: JM
authors.lastname: Pogue
authors.forename: Judy
authors.initials: J
authors.lastname: Moshos
authors.forename: Suchitha
authors.initials: S
authors.lastname: Bheemreddy
authors.forename: Bharath
authors.initials: B
authors.lastname: Sunkara
authors.forename: Alex
authors.initials: A
authors.lastname: Shallal
authors.forename: Neelu
authors.initials: N
authors.lastname: Chugh
authors.forename: Sara
authors.initials: S
authors.lastname: Eiseler
authors.forename: Pragati
authors.initials: P
authors.lastname: Bhargava
authors.forename: Christopher
authors.initials: C
authors.lastname: Blunden
authors.forename: Paul R
authors.initials: PR
authors.lastname: Lephart
authors.forename: Babar Irfan
authors.initials: BI
authors.lastname: Memon
authors.forename: Kayoko
authors.initials: K
authors.lastname: Hayakawa
authors.forename: Odaliz
authors.initials: O
authors.lastname: Abreu-Lanfranco
authors.forename: Teena
authors.initials: T
authors.lastname: Chopra
authors.forename: L Silvia
authors.initials: LS
authors.lastname: Munoz-Price
authors.forename: Yehuda
authors.initials: Y
authors.lastname: Carmeli
authors.forename: Keith S
authors.initials: KS
authors.lastname: Kaye
mesh_terms: D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D015331:Cohort Studies; D003428:Cross Infection / Q000188:drug therapy / Q000382:microbiology; D024881:Drug Resistance, Bacterial; D004755:Enterobacteriaceae / Q000187:drug effects* / Q000201:enzymology; D004756:Enterobacteriaceae Infections / Q000188:drug therapy* / Q000382:microbiology; D000077727:Ertapenem; D004927:Escherichia coli Infections / Q000188:drug therapy / Q000382:microbiology; D005260:Female; D006801:Humans; D007710:Klebsiella Infections / Q000188:drug therapy / Q000382:microbiology; D007711:Klebsiella pneumoniae; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D016896:Treatment Outcome; D001618:beta-Lactamases / Q000378:metabolism*; D047090:beta-Lactams / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D047090:beta-Lactams; D001618:beta-Lactamases; D000077727:Ertapenem